Previous Close | 0.5165 |
Open | 0.5159 |
Bid | 0.5293 x 1500 |
Ask | 0.5523 x 1500 |
Day's Range | 0.5100 - 0.5500 |
52 Week Range | 0.5010 - 5.8500 |
Volume | |
Avg. Volume | 1,217,006 |
Market Cap | 25.712M |
Beta (5Y Monthly) | 1.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobetasol propionate ophthalmic suspension 0.05% for post-surgical management of pain and inflammation; both represent large multi-million-dollar opportunitiesCompany exploring wide range of strategic alternatives NEW
Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston Will also demonstrate and discuss commercial terms for Mydcombi at the Vision Source Exchange, April 10-13, in Orlando NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conduc
Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to MicroPine for progressive pediatric myopia in the U.S. and Canada Continued to advance commercial operations with launch of Mydcombi™, FDA approval of manufacturing facility, onboarding of sales organization and signing of copromotion agreement Company to host conference call and webcast today, March 1